PCM
CNCR

Prelude Capital Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Prelude Capital Management’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,050
Closed -$291K – 1755
2018
Q2 		$291K Buy
+12,050
New +$325K 0.02% 672

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return

Prelude Capital Management's CNCR Position: Q3 2018 in Review

Prelude Capital Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2018, closing a stake of 12,050 shares — an estimated $291K sold.

Prelude Capital Management first reported a position in CNCR in Q2 2018 and held it in 1 quarter. The position peaked at $291K in Q2 2018. 23 funds tracked by Wall St. Rank hold CNCR as of Q3 2018.

  • Prelude Capital Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2018 after selling out during the quarter.
  • Prelude Capital Management sold 12,050 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2018, an estimated $291K.
  • Prelude Capital Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2018 and held it in 1 quarter.
  • Prelude Capital Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $291K in Q2 2018.
  • 23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2018.

Based on Prelude Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.